The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The April 30 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Amgen Inc. (NASDAQ: AMGN) saw its short interest decrease to 9.92 million shares from the previous level of 10.89 million. Shares were last seen trading at $172.87, in a 52-week range of $169.36 to $210.19.
[natviounit]
Short interest in Biogen Inc. (NASDAQ: BIIB) shrank to 3.96 million shares from the previous 4.10 million. The stock recently traded at $228.47, within a 52-week range of $216.12 to $388.67.
Celgene Corp.’s (NASDAQ: CELG) short interest for this settlement date decreased to 11.47 million shares from the previous level of 13.77 million. Shares were changing hands at $95.47, in a 52-week range of $58.59 to $97.07.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest slip to 13.46 million shares from 13.81 billion in the previous period. Shares were trading at $66.13, in a 52-week range of $60.32 to $79.61.
The number of MannKind Corp. (NASDAQ: MNKD) shares short increased slightly to 34.79 million. The previous reading was 34.03 million. The stock was last seen at $1.34 a share, in a 52-week range of $0.94 to $3.04.
Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest declined to 3.69 million shares from the previous 3.79 million. Shares were trading at $131.77, in a 52-week range of $92.56 to $141.86.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
